Diagnostic major Dr Lal PathLabs Limited delivered a solid performance in Q4 FY26, reporting robust top-line growth and steady profitability, according to its latest financial disclosure.

 

The company posted revenue of Rs. 703 crore in Q4 FY26, marking a 16.6% year-on-year increase, underscoring sustained demand for diagnostic and healthcare services.

 

Profitability remained healthy, with EBITDA rising 10.5% and margins holding at 26.6%. Net profit (PAT) for the quarter stood at Rs. 132 crore, translating into a PAT margin of 18.8%.

Rewarding shareholders, the board declared a final dividend of 40% (Rs. 4 per share).

 

The balance sheet also remained strong, with cash and cash equivalents of Rs. 1,526 crore as of March 31, 2026, providing significant financial flexibility going forward.

 

The results reinforce Dr Lal PathLabs’ position as one of India’s leading diagnostic service providers, with steady growth across revenue and profitability metrics.